连接慢性炎症与消化系统癌：先天淋巴细胞在肿瘤微环境中的关键作用
Bridging Chronic Inflammation and Digestive Cancer: The Critical Role of Innate Lymphoid Cells in Tumor Microenvironments
DOI 原文链接
用sci-hub下载
如无法下载，请从 Sci-Hub 选择可用站点尝试。
影响因子:10
分区:生物学1区 Top / 生化与分子生物学2区
发表日期:2024
作者:
Guanliang Shen, Qi Wang, Zhengrui Li, Jiaheng Xie, Xinda Han, Zehao Wei, Pengpeng Zhang, Songyun Zhao, Xiumei Wang, Xufeng Huang, Min Xu
DOI:
10.7150/ijbs.96338
摘要
消化系统相关癌症的发病率和死亡率一直居高不下，原因在于消化系统免疫微环境的异质性和复杂性。此外，许多研究表明，消化系统的慢性炎症是癌症发生的重要原因，因此，控制炎症成为阻止癌症发展的潜在策略。先天淋巴细胞（ILC）是一类异质性淋巴细胞，与T细胞相对，其通过与细胞因子和免疫细胞的相互作用，在抗原非依赖的方式下发挥作用。在消化系统癌症中，从炎症阶段到肿瘤的发生、迁移和转移，ILC被发现与免疫微环境相互作用，既能控制也能促进这些过程。传统治疗方法对消化肿瘤的疗效有限，因此，ILC相关的免疫治疗具有广阔前景。本文综述了不同ILC亚群的特征，它们如何影响免疫微环境及慢性炎症，以及它们在胰腺、结直肠、胃和肝细胞癌等四种常见消化系统肿瘤中的促或抑制作用。特别强调了ILC在连接慢性炎症与癌症中的作用，以及通过细胞因子疗法和过继免疫细胞疗法增强免疫治疗的潜力。
Abstract
The incidence and mortality of digestive system-related cancers have always been high and attributed to the heterogeneity and complexity of the immune microenvironment of the digestive system. Furthermore, several studies have shown that chronic inflammation in the digestive system is responsible for cancer incidence; therefore, controlling inflammation is a potential strategy to stop the development of cancer. Innate Lymphoid Cells (ILC) represent a heterogeneous group of lymphocytes that exist in contrast to T cells. They function by interacting with cytokines and immune cells in an antigen-independent manner. In the digestive system cancer, from the inflammatory phase to the development, migration, and metastasis of tumors, ILC have been found to interact with the immune microenvironment and either control or promote these processes. The conventional treatments for digestive tumors have limited efficacy, therefore, ILC-associated immunotherapies are promising strategies. This study reviews the characterization of different ILC subpopulations, how they interact with and influence the immune microenvironment as well as chronic inflammation, and their promotional or inhibitory role in four common digestive system tumors, including pancreatic, colorectal, gastric, and hepatocellular cancers. In particular, the review emphasizes the role of ILC in associating chronic inflammation with cancer and the potential for enhanced immunotherapy with cytokine therapy and adoptive immune cell therapy.